First Time Loading...

CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 278.45 AUD -0.19% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. [ Read More ]

The intrinsic value of one CSL stock under the Base Case scenario is 235.8 AUD. Compared to the current market price of 278.45 AUD, CSL Ltd is Overvalued by 15%.

Key Points:
CSL Intrinsic Value
Base Case
235.8 AUD
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
CSL Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CSL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
CSL Ltd

Provide an overview of the primary business activities
of CSL Ltd.

What unique competitive advantages
does CSL Ltd hold over its rivals?

What risks and challenges
does CSL Ltd face in the near future?

Summarize the latest earnings call
of CSL Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CSL Ltd.

Provide P/S
for CSL Ltd.

Provide P/E
for CSL Ltd.

Provide P/OCF
for CSL Ltd.

Provide P/FCFE
for CSL Ltd.

Provide P/B
for CSL Ltd.

Provide EV/S
for CSL Ltd.

Provide EV/GP
for CSL Ltd.

Provide EV/EBITDA
for CSL Ltd.

Provide EV/EBIT
for CSL Ltd.

Provide EV/OCF
for CSL Ltd.

Provide EV/FCFF
for CSL Ltd.

Provide EV/IC
for CSL Ltd.

Show me price targets
for CSL Ltd made by professional analysts.

What are the Revenue projections
for CSL Ltd?

How accurate were the past Revenue estimates
for CSL Ltd?

What are the Net Income projections
for CSL Ltd?

How accurate were the past Net Income estimates
for CSL Ltd?

What are the EPS projections
for CSL Ltd?

How accurate were the past EPS estimates
for CSL Ltd?

What are the EBIT projections
for CSL Ltd?

How accurate were the past EBIT estimates
for CSL Ltd?

Compare the revenue forecasts
for CSL Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CSL Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CSL Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of CSL Ltd compared to its peers.

Compare the P/E ratios
of CSL Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing CSL Ltd with its peers.

Analyze the financial leverage
of CSL Ltd compared to its main competitors.

Show all profitability ratios
for CSL Ltd.

Provide ROE
for CSL Ltd.

Provide ROA
for CSL Ltd.

Provide ROIC
for CSL Ltd.

Provide ROCE
for CSL Ltd.

Provide Gross Margin
for CSL Ltd.

Provide Operating Margin
for CSL Ltd.

Provide Net Margin
for CSL Ltd.

Provide FCF Margin
for CSL Ltd.

Show all solvency ratios
for CSL Ltd.

Provide D/E Ratio
for CSL Ltd.

Provide D/A Ratio
for CSL Ltd.

Provide Interest Coverage Ratio
for CSL Ltd.

Provide Altman Z-Score Ratio
for CSL Ltd.

Provide Quick Ratio
for CSL Ltd.

Provide Current Ratio
for CSL Ltd.

Provide Cash Ratio
for CSL Ltd.

What is the historical Revenue growth
over the last 5 years for CSL Ltd?

What is the historical Net Income growth
over the last 5 years for CSL Ltd?

What is the current Free Cash Flow
of CSL Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for CSL Ltd.

Financials

Balance Sheet Decomposition
CSL Ltd

Current Assets 10.1B
Cash & Short-Term Investments 1B
Receivables 3.6B
Other Current Assets 5.6B
Non-Current Assets 27.2B
Long-Term Investments 161m
PP&E 9.6B
Intangibles 16.5B
Other Non-Current Assets 968m
Current Liabilities 4.7B
Accounts Payable 2.9B
Short-Term Debt 6m
Other Current Liabilities 1.8B
Non-Current Liabilities 15.4B
Long-Term Debt 10.7B
Other Non-Current Liabilities 4.7B
Efficiency

Earnings Waterfall
CSL Ltd

Revenue
14.2B USD
Cost of Revenue
-6.9B USD
Gross Profit
7.3B USD
Operating Expenses
-3.7B USD
Operating Income
3.7B USD
Other Expenses
-1.2B USD
Net Income
2.5B USD

Free Cash Flow Analysis
CSL Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CSL Profitability Score
Profitability Due Diligence

CSL Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive Free Cash Flow
Positive Operating Income
60/100
Profitability
Score

CSL Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

CSL Solvency Score
Solvency Due Diligence

CSL Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
59/100
Solvency
Score

CSL Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CSL Price Targets Summary
CSL Ltd

Wall Street analysts forecast CSL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CSL is 307.59 AUD with a low forecast of 233.7 AUD and a high forecast of 355.43 AUD.

Lowest
Price Target
233.7 AUD
16% Downside
Average
Price Target
307.59 AUD
10% Upside
Highest
Price Target
355.43 AUD
28% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

CSL Price
CSL Ltd

1M 1M
-2%
6M 6M
+18%
1Y 1Y
-9%
3Y 3Y
+5%
5Y 5Y
+48%
10Y 10Y
+361%
Annual Price Range
278.45
52w Low
230.65
52w High
310.73
Price Metrics
Average Annual Return 11.59%
Standard Deviation of Annual Returns 19.67%
Max Drawdown -30%
Shares Statistics
Market Capitalization 134.5B AUD
Shares Outstanding 484 984 333
Percentage of Shares Shorted
N/A

CSL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

CSL Ltd Logo
CSL Ltd

Country

Australia

Industry

Biotechnology

Market Cap

134.5B AUD

Dividend Yield

1.36%

Description

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 25,000 full-time employees. The firm is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. The company offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The firm operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.

Contact

VICTORIA
Melbourne
45 Poplar Road,, Parkville
+61393891911.0
https://www.csl.com/

IPO

1994-06-08

Employees

25 000

Officers

MD, CEO & Executive Director
Dr. Paul F. McKenzie Ph.D.
Chief Financial Officer
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI
Head of Investor Relations
Mr. Mark Dehring
Executive VP of Legal & General Counsel
Mr. Gregory Boss B.S., BS(Hons), J.D.
Senior Manager of Communications
Christina Hickie
Chief Human Resources Officer
Ms. Roanne Parry
Show More
Executive Vice President of Quality & Business Services
Dr. Karen Etchberger
Head of Communications - Asia Pacific
Ms. Jemimah Brennan
Senior Vice President of Research
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.
Executive VP & Head of Research and Development
Dr. William Mezzanotte M.D., M.P.H.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CSL stock?

The intrinsic value of one CSL stock under the Base Case scenario is 235.8 AUD.

Is CSL stock undervalued or overvalued?

Compared to the current market price of 278.45 AUD, CSL Ltd is Overvalued by 15%.